pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
General criteria for global responses to antifungal therapy
| Outcomes, response | Criteria |
|---|---|
| Treatment success | |
| Complete response | Survival within the prespecified period of all attributable symptoms and signs of disease and radiological abnormalities, and mycological evidence of eradication of disease |
| Partial response | Survival within the prespecified period of observation, improvement in attributable symptoms and signs of disease and radiological abnormalities, and evidence of clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker |
| Lack of response | |
| Stable disease | Survival within the prespecified period of observation and minor or no improvement in fungal disease, but no evidence of progression, as determined on the basis of a composite of clinical, radiological, and mycological criteria |
| Progression of fungal disease | Evidence of progressive fungal disease based on a composite of clinical, radiological, and mycological criteria |
| Death | Death during the prespecified period of evaluation, regardless of attribution |
In certain invasive fungal diseases(e.g., invasive mold diseases), stabilization of fungal disease during periods of severe immunocompromise provides evidence of efficacy of treatment and may be a reasonable short-term therapeutic goal until immune recovery occurs.